Burning Rock Biotech (Burning Rock Biotech) Cash-to-Debt

: 33.33 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Burning Rock Biotech's cash to debt ratio for the quarter that ended in Sep. 2023 was 33.33.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Burning Rock Biotech could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Burning Rock Biotech's Cash-to-Debt or its related term are showing as below:

BNR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48 Med: 17.16 Max: 52.6
Current: 33.33

During the past 6 years, Burning Rock Biotech's highest Cash to Debt Ratio was 52.60. The lowest was 0.48. And the median was 17.16.

BNR's Cash-to-Debt is ranked better than
89.7% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.44 vs BNR: 33.33

Burning Rock Biotech Cash-to-Debt Historical Data

The historical data trend for Burning Rock Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

0.48

6.05

48.15

17.25

17.83

Burning Rock Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt																16.42	17.83	19.14	24.00	33.33

Competitive Comparison

For the Diagnostics & Research subindustry, Burning Rock Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech Cash-to-Debt Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Cash-to-Debt falls into.

Burning Rock Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Burning Rock Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	129.875	/	(5.341	+	1.944)
	=	17.83

Burning Rock Biotech's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	87.189	/	(1.916	+	0.7)
	=	33.33

Burning Rock Biotech (NAS:BNR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Burning Rock Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech (Burning Rock Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BNR:UK 6BUA:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.